These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 17313157)

  • 1. Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
    Cianfrocca M; Wolff AC
    Oncology (Williston Park); 2007 Jan; 21(1):63-9; discussion 69, 72, 75 passim. PubMed ID: 17313157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity and endocrine therapy: host factors and breast cancer outcome.
    Goodwin PJ
    Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
    Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
    Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
    Pritchard KI
    Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
    Nabholtz JM
    Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant endocrine therapy in premenopausal women with breast cancer.
    González Martín A; de la Cruz S; Márquez R
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
    [No Abstract]   [Full Text] [Related]  

  • 12. New developments in the treatment of postmenopausal breast cancer.
    Howell A
    Trends Endocrinol Metab; 2005 Nov; 16(9):420-8. PubMed ID: 16213745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
    N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Koeberle D; Thuerlimann B
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):5-10. PubMed ID: 16375638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.
    Goldhirsch A
    Breast; 2013 Aug; 22 Suppl 2():S3-7. PubMed ID: 24074788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
    Aapro M; van de Velde CJ; Markopoulos C; Bartlett JM; Putter H; Coleman RE
    Breast; 2013 Aug; 22(4):488-94. PubMed ID: 23454040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
    Baum M
    Eur J Cancer; 2005 Aug; 41(12):1667-77. PubMed ID: 16046117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming recurrence risk: extended adjuvant endocrine therapy.
    Cianfrocca M
    Clin Breast Cancer; 2008 Dec; 8(6):493-500. PubMed ID: 19073503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.